Recipharm, a Swiss-based CDMO owned by private equity firm EQT, has completed a refinancing that extends its debt maturity profile by seven years, alongside improved credit ratings from S&P Global Ratings and Moody’s Ratings.

Recipharm employs over 4,500 people and operates 17 sites across Europe, the US and India, providing oral solid dosage, sterile fill and finish and advanced biologics services. EQT acquired the company in February 2021 through a public takeover offer, together with its founders Thomas Eldered and Lars Backsell.

According to S&P, the refinancing comprises a new €880m (US$980m) term loan B and an undrawn revolving credit facility of up to €200m maturing in January 2033. It completes the financial separation of Bespak, a UK-based inhalation and advanced delivery business that was operationally carved out in April 2024 to form a separate EQT portfolio company.

S&P expects the transaction to reduce its adjusted debt to €1.0bn from €1.5bn in 2025. Excluding Bespak, Recipharm generated sales of €837m in 2025, up 1.2% year on year.

Moody’s assigned a corporate family rating of B2 with a stable outlook. S&P assigned Recipharm Holding a long-term issuer credit rating of B with a stable outlook and upgraded Roar BidCo, a lower entity in the group structure, to B from B-. Fitch affirmed its long-term issuer default rating of B with a stable outlook.

“These results reflect the strength of our business and the confidence our lenders and ratings agencies place in our long-term strategy,” said Greg Behar, CEO of Recipharm. “This refinancing gives us a stronger financial platform and greater capacity to invest in the sites, technologies and people that deliver for our customers, and ultimately patients, every day.”

Fitch said the stable outlook reflects expected profitable growth leading to EBITDA leverage below 5.0x from 2027. S&P forecasts adjusted debt to EBITDA of 5.5x-6.0x in 2026 and organic revenue growth of 7.0%-7.5% a year over 2027 and 2028.

Press release: Recipharm completes refinancing and secures improved credit ratings | Recipharm